Autologous Hematopoietic Stem Cell Transplantation for Type 1 Diabetes


Autoria(s): VOLTARELLI, Julio C.; COURI, Carlos E. B.; STRACIERI, Ana B. P. L.; OLIVEIRA, Maria C.; MORAES, Daniela A.; PIERONI, Fabiano; BARROS, George M. N.; MADEIRA, Maria Isabel A.; MALMEGRIM, Kelen C. R.; FOSS-FREITAS, Maria C.; SIMOES, Belinda P.; FOSS, Milton C.; SQUIERS, Elizabeth; BURT, Richard K.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2008

Resumo

In this review, we present (1) the scientific basis for the use of high-dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for newly diagnosed type 1 diabetes (T1D); (2) an update of the clinical and laboratory outcome of 20 patients transplanted at the University Hospital of the Ribeirao Preto Medical School, University of Sao Paulo, Brazil, and followed up to January/2008, including 4 relapses among 19 patients without previous ketoacidosis; (3) a commentary on criticisms to our article that appeared in four articles from the scientific literature; and (4) a discussion of the prospectives for cellular therapy for T1D.

CNPq

FAPESP FINEP

CAPES

FAEPA

FUNDHERP

Identificador

Annals of the New York Academy of Sciences, v.1150, p.220-229, 2008

978-1-57331-733-7

0077-8923

http://producao.usp.br/handle/BDPI/25030

10.1196/annals.1447.048

http://dx.doi.org/10.1196/annals.1447.048

Idioma(s)

eng

Publicador

BLACKWELL PUBLISHING

Relação

Annals of the New York Academy of Sciences

Direitos

closedAccess

Copyright BLACKWELL PUBLISHING

Palavras-Chave #type 1 diabetes #stem cell transplantation #high-dose immunosuppression #BONE-MARROW-TRANSPLANTATION #AUTOIMMUNE-DISEASES #ONSET #THERAPY #TOLERANCE #MELLITUS #MICE #Multidisciplinary Sciences
Tipo

article

proceedings paper

publishedVersion